

· 论 文 ·

## 一种查耳酮类化合物的合成方法

罗维贤<sup>1</sup>, 杨礼寿<sup>2</sup>, 杨小生<sup>2,3\*</sup>

(<sup>1</sup>贵州大学药学院, 贵阳 550025; <sup>2</sup>贵州医科大学省部共建药用植物功效与利用国家重点实验室, 贵阳 550000; <sup>3</sup>贵州省中国科学院天然产物化学重点实验室, 贵阳 550014)

**摘要** 建立一种以取代苯乙酮和取代苯甲醛为原料, 采用多聚磷酸/浓硫酸体系催化合成查耳酮类化合物的方法, 并对反应条件进行优化。结果表明, 最优反应条件为多聚磷酸 5 equiv.、浓硫酸 20 equiv. , 1,4-二氧六环作溶剂, 90 °C 氮气保护下反应 2 h。在优化的反应条件下, 以较好的得率合成了 12 个查耳酮类化合物。所有化合物结构通过 IR、HRMS、<sup>1</sup>H NMR 和 <sup>13</sup>C NMR 进行表征。

**关键词** 查耳酮类化合物; 缩合反应; 多聚磷酸/浓硫酸; 苯乙酮; 苯甲醛; 合成

中图分类号 O621.3 文献标志码 A 文章编号 1000-5048(2020)05-0509-05

doi: 10.11665/j.issn.1000-5048.20200501

引用本文 罗维贤, 杨礼寿, 杨小生. 一种查耳酮类化合物的合成方法[J]. 中国药科大学学报, 2020, 51(5): 509-513.

Cite this article as: LUO Weixian, YANG Lishou, YANG Xiaosheng. A method for the synthesis of chalcones[J]. *J China Pharm Univ*, 2020, 51(5): 509-513.

## A method for the synthesis of chalcones

LUO Weixian<sup>1</sup>, YANG Lishou<sup>2</sup>, YANG Xiaosheng<sup>2,3\*</sup>

<sup>1</sup>College of Pharmacy, Guizhou University, Guiyang 550025; <sup>2</sup>State Key Laboratory of Functions and Applications of Medicinal Plants, Guizhou Medical University, Guiyang 550000; <sup>3</sup>Key Laboratory of Chemistry for Natural Products of Guizhou Province and Chinese Academy of Sciences, Guiyang 550014, China

**Abstract** In this paper, a new method for catalytic synthesis of chalcones from substituted acetophenone and substituted benzaldehyde in polyphosphoric acid/concentrated sulfuric acid system was proposed, and the reaction conditions were optimized. The results showed that the optimized reaction conditions were determined as polyphosphoric acid of 5 equiv. and concentrated sulfuric acid of 20 equiv. , with 1,4-dioxane as solvent at 90 °C for 2 h under nitrogen protection. Twelve chalcones were synthesized with good yield. All target compounds were characterized by IR, HRMS, <sup>1</sup>H NMR and <sup>13</sup>C NMR.

**Key words** chalcones; condensation; polyphosphoric acid/H<sub>2</sub>SO<sub>4</sub>; acetophenones; benzaldehydes; synthesis

The study was supported by the National Natural Science Foundation of China(No. 81860609), the Natural Science Foundation of Guizhou Province(No. QKHJC[2019]1213), and the High-level Innovative Talents Training in Guizhou Province(No. QKHRC[2015]4027)


查耳酮是许多天然存在的化合物中最常见的骨架之一, 研究发现查耳酮类化合物的生物活性

较为广泛, 例如肿瘤、炎症和糖尿病。查耳酮类化合物美托查酮(metochalcone)和索法酮(sofalcone)

收稿日期 2020-04-25 \*通信作者 Tel: 13595099817 E-mail: gzcnp@sina.cn

基金项目 国家自然科学基金资助项目(No. 8186130139); 贵州省自然科学基金资助项目(黔科合基础[2019]1213号); 贵州省高层次创新型人才项目(黔科合人才[2015]4027号)

曾分别作为抗胆碱药和抗溃疡药应用于临床。查耳酮化合物由于自身结构的柔性能够与诸多受体相结合,从而体现出了许多生物活性,如抗蛲虫、抗过敏、抗肿瘤、抗氧自由基、抗菌、抗病毒、抗溃疡和解痉挛。合成查耳酮类化合物经典的合成方法为碱或酸催化的 Claisen-Schmidt 缩合<sup>[1]</sup>。常使用的碱催化剂有氢氧化钠、氢氧化钾、碱土金属氢氧化物、双(三甲硅基)酰胺锂和哌嗪。酸催化剂有氯化氢、三氯化铝、四氯化钛、氯化钌、三氟化硼、对甲苯磺酸。也有文献报道了研磨法<sup>[2]</sup>、微波加热法<sup>[3]</sup>以及水作为溶剂相转移催化法<sup>[4]</sup>合成查耳酮类衍生物。但是 Claisen-Schmidt 缩合存在反



**Scheme 1** Synthesis route of chalcones

PPA: Polyphosphoric acid

## 1 试剂和仪器

多聚磷酸(PPA, 纯度大于80%, 海业联联合化工有限责任公司);浓硫酸(纯度98%, 重庆川江化学试剂厂);1,4-二氧六环[纯度99.7%, 重庆川东化工(集团)有限公司];其他试剂均为市售分析纯。

INOVA 600 MHz 核磁共振仪(TMS内标)、Impact HD Q-TOF型高分辨质谱仪(德国Bruker公司);红外光谱仪(天津港东科技股份有限公司);XT-4型显微熔点测定仪(北京泰光仪器有限公司)。

## 2 目标化合物的合成


### 2.1 反应条件的优化

以苯甲醛(0.8 mmol)和苯乙酮(1.0 mmol)为反应底物,优化反应条件。分别考察PPA用量、浓硫酸用量、反应温度、反应时间、酸的种类以及溶剂种类对反应的影响,筛选出最优反应条件。

### 2.2 反应底物的拓展

以化合物3a为例,在优化好的实验条件基础上,取PPA(5.0 mmol)加入20 mL圆底烧瓶中,再依次加入1,4-二氧六环(3.5 mL)、浓硫酸(20.0

应时间较长、常伴有副产物或反应不彻底导致难以分离的缺点<sup>[5]</sup>。除了经典缩合反应外,交叉偶联法(Suzuki反应<sup>[5]</sup>、Heck反应<sup>[6]</sup>、Julia-Kocienski反应<sup>[7]</sup>、Wittig反应<sup>[8]</sup>)和Friedel-Crafts酰化反应也常用于查耳酮类化合物的合成<sup>[9]</sup>,但总体得率不理想。因此,开发简便、高效、反应条件温和的查耳酮类化合物的合成方法具有重要意义。本研究以1,4-二氧六环(1,4-dioxane)为溶剂,PPA/H<sub>2</sub>SO<sub>4</sub>体系催化苯乙酮和苯甲醛缩合合成系列查耳酮类化合物(路线1)。此方法操作简单、反应条件温和、产率高且所使用的催化剂成本低。



mmol)、苯甲醛(0.8 mmol)和苯乙酮(1.0 mmol),于90 °C氮气保护下油浴搅拌加热反应,2 h反应结束。用乙酸乙酯、饱和食盐水萃取,有机相减压浓缩后经柱色谱分离纯化得到化合物3a,洗脱剂为石油醚-乙酸乙酯(50:1)。以相同条件合成查耳酮化合物12个,所有化合物经核磁共振氢谱(<sup>1</sup>H NMR)、核磁共振碳谱(<sup>13</sup>C NMR)、高分辨质谱(HRMS)、红外波谱(IR)和熔点仪表征,理化性质数据列于表1,核磁表征数据列于表2。

## 3 结果与讨论

### 3.1 反应条件的优化

多聚磷酸(PPA)在有机合成中用作失水剂、环化剂、酰化剂,是缩合、环化、重排、取代等反应的催化剂或溶剂。本研究以苯甲醛(0.8 mmol)和苯乙酮(1.0 mmol)为反应底物,优化反应条件。考察了PPA用量、浓硫酸用量、反应温度、反应时间、酸的种类以及溶剂种类对反应的影响。薄层色谱(TLC)监测反应进程,反应结束后分离得到目标化合物,比较了不同条件下的产率,从而筛选出最佳反应条件,结果列于表3。

PPA 用量为 10 equiv., 浓硫酸 用量为 15 equiv., 以二氧六环为溶剂, 90 °C 搅拌反应 2 h, 以

**Table 1** Appearance, yields, melting points, HRMS and IR data of compounds 3a–3l

Compd.	Appearance	Yield/%	mp/°C	HRMS, <i>m/z</i> [M+H] <sup>+</sup> (calcd.)	IR(KBr), $\nu_{\max}$ /cm <sup>-1</sup>
<b>3a</b>	White solid	96	51–54(54–56 <sup>[10]</sup> )	208.112 8(208.088 8)	1 648, 1 585, 1 563, 819, 760, 720, 690
<b>3b</b>	Yellow solid	95	92–95(95–96 <sup>[11]</sup> )	222.105 6(222.104 4)	1 642, 1 575, 1 555, 810, 765, 728, 693
<b>3c</b>	Yellow solid	90	63–64(58–60 <sup>[12]</sup> )	238.146 7(238.099 4)	1 667, 1 560, 1 588, 849, 754, 740, 686
<b>3d</b>	Yellow solid	82	54–55(50–52 <sup>[13]</sup> )	242.125 8(242.049 8)	1 682, 1 577, 1 542, 807, 752, 701, 640
<b>3e</b>	Light red solid	83	120–122(122–123 <sup>[14]</sup> )	285.864 7(285.999 3)	1 686, 1 592, 1 535, 820, 778, 734, 682
<b>3f</b>	Yellow solid	86	77–79	240.115 8(240.095 0)	1 661, 1 581, 1 569, 849, 780, 742, 710
<b>3g</b>	Yellow solid	80	75–78	276.102 4(276.010 8)	1 650, 1 580, 1 572, 818, 750, 710, 688
<b>3h</b>	Light red solid	91	60–64(50–51 <sup>[15]</sup> )	222.148 7(222.104 5)	1 653, 1 574, 1 562, 852, 776, 740, 696
<b>3i</b>	Light red solid	91	124–127(128–130 <sup>[16]</sup> )	236.158 8(236.120 1)	1 679, 1 595, 1 576, 855, 774, 738, 712
<b>3j</b>	Red oil	92	/	252.164 1(252.115 0)	1 687, 1 592, 1 525, 841, 777, 741, 682
<b>3k</b>	Light red solid	88	74–76	256.126 6(256.065 4)	1 669, 1 594, 1 542, 852, 760, 740, 668
<b>3l</b>	Orange solid	86	79–81(79–80 <sup>[17]</sup> )	272.108 6(272.060 4)	1 622, 1 590, 1 560, 849, 761, 725, 687

**Table 2** <sup>1</sup>H NMR and <sup>13</sup>C NMR data of compounds 3a–3l

Compd.	<sup>1</sup> H NMR (600 MHz, CDCl <sub>3</sub> ), $\delta$	<sup>13</sup> C NMR (150 MHz, CDCl <sub>3</sub> ), $\delta$
<b>3a</b>	8.03(s, 1H, Ph-H), 8.02(d, <i>J</i> =1.3 Hz, 1H, Ph-H), 7.82(d, <i>J</i> =15.7 Hz, 1H, $\beta$ -H), 7.65(dd, <i>J</i> =6.5, 3.0 Hz, 2H, $\alpha$ -H, Ph-H), 7.59(t, <i>J</i> =7.4 Hz, 1H, Ph-H), 7.55(s, 1H, Ph-H), 7.52(dd, <i>J</i> =12.4, 4.4 Hz, 3H, Ph-H), 7.43(dd, <i>J</i> =5.0, 1.8 Hz, 3H, Ph-H)	190.93, 145.21, 138.57, 135.24, 133.14, 130.90, 129.32, 128.98, 128.86, 128.80, 122.46
<b>3b</b>	8.03(s, 1H, Ph-H), 8.01(d, <i>J</i> =1.4 Hz, 1H, Ph-H), 7.80(d, <i>J</i> =15.7 Hz, 1H, $\beta$ -H), 7.58(d, <i>J</i> =7.4 Hz, 1H, $\alpha$ -H), 7.55(d, <i>J</i> =8.1 Hz, 2H, Ph-H), 7.52–7.50(m, 2H, Ph-H), 7.49(d, <i>J</i> =4.0 Hz, 1H, Ph-H), 7.23(d, <i>J</i> =7.9 Hz, 2H, Ph-H), 2.40(s, 3H, -CH <sub>3</sub> -H)	191.00, 145.29, 141.43, 138.70, 133.00, 132.50, 130.05, 128.93, 128.81, 121.44, 21.88
<b>3c</b>	8.05(d, <i>J</i> =2.0 Hz, 1H, Ph-H), 8.04(d, <i>J</i> =2.0 Hz, 1H, Ph-H), 7.81(d, <i>J</i> =15.7 Hz, 1H, $\beta$ -H), 7.64(dd, <i>J</i> =7.4, 2.0 Hz, 2H), 7.55(d, <i>J</i> =15.7 Hz, 1H, $\alpha$ -H), 7.42–7.40(m, 3H, Ph-H), 6.99(d, <i>J</i> =8.9 Hz, 2H, Ph-H), 3.89(s, 3H, -OCH <sub>3</sub> -H)	189.07, 163.78, 144.31, 135.43, 131.44, 131.16, 130.67, 129.26, 128.70, 122.24, 114.20, 55.84
<b>3d</b>	8.18(d, <i>J</i> =15.8 Hz, 1H, $\beta$ -H), 8.03(s, 1H, Ph-H), 8.01(d, <i>J</i> =1.3 Hz, 1H, $\alpha$ -H), 7.76–7.74(m, 1H, Ph-H), 7.59(t, <i>J</i> =7.4 Hz, 1H, Ph-H), 7.50(dd, <i>J</i> =9.7, 5.7 Hz, 3H, Ph-H), 7.47(s, 1H, Ph-H), 7.45–7.42(m, 1H, Ph-H), 7.34–7.30(m, 2H, Ph-H)	190.32, 140.51, 137.81, 135.38, 133.14, 132.84, 131.08, 130.19, 128.56, 128.52, 127.68, 126.99, 124.69
<b>3e</b>	8.02(s, 1H, Ph-H), 8.01(d, <i>J</i> =1.3 Hz, 1H, Ph-H), 7.74(d, <i>J</i> =15.7 Hz, 1H, $\beta$ -H), 7.60(t, <i>J</i> =7.4 Hz, 1H, Ph-H), 7.55(d, <i>J</i> =8.5 Hz, 2H, $\alpha$ -H), 7.53(d, <i>J</i> =6.2 Hz, 1H, Ph-H), 7.51(d, <i>J</i> =2.1 Hz, 3H, Ph-H), 7.50(s, 1H, Ph-H)	189.86, 142.99, 137.63, 133.43, 132.58, 131.84, 129.42, 128.31, 128.13, 124.43, 122.19
<b>3f</b>	8.05(s, 1H, Ph-H), 8.04(d, <i>J</i> =1.4 Hz, 1H, Ph-H), 7.91(d, <i>J</i> =15.9 Hz, 1H, $\beta$ -H), 7.73(d, <i>J</i> =15.9 Hz, 1H, $\alpha$ -H), 7.59(t, <i>J</i> =7.4 Hz, 1H, Ph-H), 7.51(t, <i>J</i> =7.6 Hz, 2H, Ph-H), 7.23–7.21(m, 1H, Ph-H), 7.03(d, <i>J</i> =7.4 Hz, 1H, Ph-H), 7.01–6.97(m, 1H, Ph-H), 2.50(s, 3H, -CH <sub>3</sub> -H)	190.77, 141.01, 140.93, 138.19, 136.00, 133.04, 130.66, 130.59, 128.69, 127.30, 127.21, 126.56, 122.25, 114.08, 113.93, 20.55
<b>3g</b>	8.10(d, <i>J</i> =15.8 Hz, 1H, $\beta$ -H), 8.02–8.00(m, 2H, Ph-H), 7.68(d, <i>J</i> =8.5 Hz, 1H, $\alpha$ -H), 7.60(t, <i>J</i> =7.4 Hz, 1H, Ph-H), 7.52(d, <i>J</i> =7.9 Hz, 2H, Ph-H), 7.49(d, <i>J</i> =6.9 Hz, 1H, Ph-H), 7.46(d, <i>J</i> =2.4 Hz, 2H, Ph-H), 7.30(dd, <i>J</i> =8.4, 2.0 Hz, 1H, Ph-H)	190.24, 139.46, 137.90, 136.60, 136.20, 133.21, 131.98, 130.27, 128.84, 128.74, 128.63, 127.69, 125.15
<b>3h</b>	7.95(s, 1H, Ph-H), 7.94(s, 1H, Ph-H), 7.81(d, <i>J</i> =15.7 Hz, 1H, $\beta$ -H), 7.65(dd, <i>J</i> =7.2, 2.2 Hz, 2H, Ph-H), 7.54(d, <i>J</i> =15.7 Hz, 1H, $\alpha$ -H), 7.42(d, <i>J</i> =2.1 Hz, 1H, Ph-H), 7.41(d, <i>J</i> =1.8 Hz, 1H, Ph-H), 7.31(d, <i>J</i> =8.0 Hz, 2H, Ph-H), 2.44(s, 3H, -CH <sub>3</sub> -H)	190.15, 144.51, 135.76, 135.12, 130.54, 129.46, 129.06, 128.78, 128.53, 122.22, 21.80
<b>3i</b>	7.95(s, 1H, Ph-H), 7.93(s, 1H, Ph-H), 7.79(d, <i>J</i> =15.7 Hz, 1H, $\beta$ -H), 7.55(s, 1H, Ph-H), 7.54(s, 1H, Ph-H), 7.50(d, <i>J</i> =15.7 Hz, 1H, $\alpha$ -H), 7.30(d, <i>J</i> =7.9 Hz, 2H, Ph-H), 7.22(d, <i>J</i> =7.9 Hz, 2H, Ph-H), 2.44(s, 3H, -CH <sub>3</sub> -H), 2.39(s, 3H, -CH <sub>3</sub> -H)	190.44, 144.81, 143.82, 141.26, 136.10, 132.60, 130.01, 129.63, 128.95, 128.76, 121.43, 21.99, 21.85

(Continued)

Compd.	<sup>1</sup> H NMR (600 MHz, CDCl <sub>3</sub> ), $\delta$	<sup>13</sup> C NMR (150 MHz, CDCl <sub>3</sub> ), $\delta$
<b>3j</b>	8.12(d, $J$ =15.9 Hz, 1H, $\beta$ -H), 7.94(s, 1H, Ph-H), 7.93(s, 1H, Ph-H), 7.63(dd, $J$ =13.2, 8.5 Hz, 2H, Ph-H, $\alpha$ -H), 7.37(t, $J$ =8.6 Hz, 1H, Ph-H), 7.30(d, $J$ =8.0 Hz, 2H, Ph-H), 6.99(t, $J$ =7.5 Hz, 1H, Ph-H), 6.94(d, $J$ =8.3 Hz, 1H, Ph-H), 3.91(s, 3H, -OCH <sub>3</sub> -H), 2.43(s, 3H, -CH <sub>3</sub> -H)	190.76, 158.89, 143.45, 140.07, 136.06, 131.75, 129.37, 129.29, 128.81, 124.18, 123.04, 120.85, 111.35, 77.37, 77.16, 76.95, 55.66, 21.79
<b>3k</b>	8.17(d, $J$ =15.8 Hz, 1H, $\beta$ -H), 7.93(d, $J$ =8.2 Hz, 2H, Ph-H), 7.74(dd, $J$ =7.0, 2.4 Hz, 1H, Ph-H), 7.48(d, $J$ =15.7 Hz, 1H, $\alpha$ -H), 7.43(dd, $J$ =6.8, 2.4 Hz, 1H, Ph-H), 7.31(d, $J$ =4.2 Hz, 1H, Ph-H), 7.29(s, 2H, Ph-H), 2.43(s, 3H, -CH <sub>3</sub> -H)	190.25, 144.21, 140.53, 135.80, 135.72, 133.73, 131.43, 130.64, 129.75, 129.15, 128.14, 127.44, 125.21, 22.07
<b>3l</b>	8.16(d, $J$ =15.7 Hz, 1H, $\beta$ -H), 8.03(d, $J$ =8.9 Hz, 2H, Ph-H), 7.76–7.73(m, 1H, Ph-H), 7.49(d, $J$ =15.7 Hz, 1H, $\alpha$ -H), 7.43(d, $J$ =7.0 Hz, 1H, Ph-H), 7.31(d, $J$ =4.3 Hz, 2H, Ph-H), 6.98(d, $J$ =8.9 Hz, 2H), 3.89(s, 3H, -OCH <sub>3</sub> -H)	189.60, 164.52, 140.75, 136.35, 134.45, 131.81, 131.25, 128.74, 128.01, 125.71, 114.87, 56.48

74% 产率获得 **3a** (表 3, Entry 1)。当浓硫酸用量增加到 20 equiv. 时, 产率升高(表 3, Entry 2), 进一步增加浓硫酸用量, 产率降低(表 3, Entry 3)。增加 PPA 用量对产率没有明显影响(表 3, Entry 6), 但是 PPA 用量减小到 5 equiv. 时, 产率达到 96% (表 3, Entry 5), 进一步减少 PPA 添加量产率也随之降低(表 3, Entry 4)。因此, 确定 PPA 和浓硫酸最佳用量分别为 5 equiv. 和 20 equiv.。之后考察了反应温度和反应时间对产率的影响, 改变反应温度和反应时间均使产率降低(表 3, Entries 7~10)。当不添加 PPA 时无化合物 **3a** 生成(表 3, Entry 11), 当不添加浓硫酸时以 8% 的产率获得化合物 **3a** (表 3, Entry 12)。由此可见 PPA 是催化苯乙酮和苯甲醛缩合生成查耳酮的必不可少的催化剂。然后, 用浓盐酸 (HCl)、磷酸 (H<sub>3</sub>PO<sub>4</sub>)、硝酸 (HNO<sub>3</sub>) 或醋酸 (AcOH) 替换浓硫酸, 考察不同种类的酸与 PPA 共同催化的效果。替换酸后, 产率极低(表 3, Entries 14~16), 甚至得不到目标产物(表 3, Entry 13)。当使用乙醇 (EtOH)、四氢呋喃 (THF)、二甲基亚砜 (DMSO) 或 *N,N*-二甲基甲酰胺 (DMF) 作溶剂时, 均未获得目标产物(表 3, Entries 17~20)。基于以上实验结果, 确定 PPA 5 equiv.、浓硫酸 20 equiv. , 在二氧六环溶剂中, 于 90 °C 反应 2 h 为最优反应条件。

### 3.2 底物的拓展

为了探索该方法的适用范围, 在最优反应条件下, 以不同取代的苯乙酮和不同取代的苯甲醛为底物, 考察了不同取代基对反应产率的影响, 结果见表 1。当苯甲醛和/或苯乙酮取代基为供电子基甲基或甲氧基或无取代时(**3a~3c, 3h~3j**), 以高

Table 3 Optimization of the reaction conditions

Entry	Additive 1 (equiv.)	Additive 2 (equiv.)	Solvent	T/°C	t/h	Yield/%
1	PPA(10)	H <sub>2</sub> SO <sub>4</sub> (15)	1,4-dioxane	90	2	74
2	PPA(10)	H <sub>2</sub> SO <sub>4</sub> (20)	1,4-dioxane	90	2	86
3	PPA(10)	H <sub>2</sub> SO <sub>4</sub> (25)	1,4-dioxane	90	2	62
4	PPA(2.5)	H <sub>2</sub> SO <sub>4</sub> (20)	1,4-dioxane	90	2	72
5	PPA(5)	H <sub>2</sub> SO <sub>4</sub> (20)	1,4-dioxane	90	2	96
6	PPA(20)	H <sub>2</sub> SO <sub>4</sub> (20)	1,4-dioxane	90	2	87
7	PPA(5)	H <sub>2</sub> SO <sub>4</sub> (20)	1,4-dioxane	80	2	83
8	PPA(5)	H <sub>2</sub> SO <sub>4</sub> (20)	1,4-dioxane	100	2	85
9	PPA(5)	H <sub>2</sub> SO <sub>4</sub> (20)	1,4-dioxane	90	1	76
10	PPA(5)	H <sub>2</sub> SO <sub>4</sub> (20)	1,4-dioxane	90	3	80
11	PPA(0)	H <sub>2</sub> SO <sub>4</sub> (20)	1,4-dioxane	90	2	/
12	PPA(5)	H <sub>2</sub> SO <sub>4</sub> (0)	1,4-dioxane	90	2	8
13	PPA(5)	HCl(20)	1,4-dioxane	90	2	/
14	PPA(5)	H <sub>3</sub> PO <sub>4</sub> (20)	1,4-dioxane	90	2	8
15	PPA(5)	HNO <sub>3</sub> (20)	1,4-dioxane	90	2	5
16	PPA(5)	AcOH(20)	1,4-dioxane	90	2	6
17	PPA(5)	H <sub>2</sub> SO <sub>4</sub> (20)	EtOH	90	2	/
18	PPA(5)	H <sub>2</sub> SO <sub>4</sub> (20)	THF	90	2	/
19	PPA(5)	H <sub>2</sub> SO <sub>4</sub> (20)	DMSO	90	2	/
20	PPA(5)	H <sub>2</sub> SO <sub>4</sub> (20)	DMF	90	2	/

THF: Tetrahydrofuran; DMSO: Dimethyl sulfoxide; DMF: *N,N*-dimethylformamide. Conditions were optimized with acetophenone (**1a**, 1.0 mmol) and benzaldehyde (**2a**, 0.8 mmol) as the substrate, and the solvent was 3.5 mL

收率(90%~96%)得到目标化合物。当反应底物苯乙酮上有吸电子基溴时, 没有获得目标产物(**3m**)。当苯甲醛上有吸电子基氟、氯或溴取代时产率降低(**3d~3f, 3k** 和 **3l**), 特别是当苯甲醛被两个吸电子基取代时产率进一步降低(**3g**)。上述结果表明, 底物上有吸电子基取代时不利于该条件下缩

合生成查耳酮。

#### 4 结 论

1,4-二氧六环为反应溶剂,于90℃氮气保护下反应2 h, PPA/H<sub>2</sub>SO<sub>4</sub>体系催化苯乙酮和苯甲醛缩合合成查耳酮,以高收率得到了12个查耳酮类化合物。该方法操作简单、反应条件温和、产率高且所使用催化剂成本低。该条件下合成的查耳酮类化合物均为E型,化合物3a~3l乙烯基质子 $\alpha$ -H(2-H)和 $\beta$ -H(3-H)分别在 $\delta$  7.4和 $\delta$  7.7左右产生两组双重峰,偶合常数大于15 Hz,与文献[18]报道的E型查耳酮 $\alpha$ -H、 $\beta$ -H化学位移一致。

#### 参 考 文 献

- [1] Kil YS, Choi SK, Lee YS, et al. Chalcones from *Angelica keiskei*: evaluation of their heat shock protein inducing activities [J]. *J Nat Prod*, 2015, **78**(10): 2481–2487.
- [2] Liu XF, Shi DH. Research progress in the synthesis of chalcone [J]. *Appl Chem Ind* (应用化工), 2012, **38**(8): 1210–1213, 1219.
- [3] Kulkarni P. Calcium oxide catalyzed synthesis of chalcone under microwave condition [J]. *Curr Microw Chem*, 2015, **2**(2): 144–149.
- [4] Duan HC, Jiang H, Gong H. Green synthesis of chalcone derivatives [J]. *China Pharm* (中国药业), 2006, **15**(15): 30–31.
- [5] Zhuang C, Zhang W, Sheng C, et al. Chalcone: a privileged structure in medicinal chemistry [J]. *Chem Rev*, 2017, **117**(12): 7762–7810.
- [6] Miyaura N, Suzuki A. Stereoselective synthesis of arylated (E)-alkenes by the reaction of alk-1-enylboranes with aryl halides in the presence of palladium catalyst [J]. *J Chem Soc Chem Commun*, 1979, **19**(19): 135–152.
- [7] Heck RF, Nolley JP. Palladium-catalyzed vinylic hydrogen substitution reactions with aryl, benzyl, and styryl halides [J]. *J Org Chem*, 1972, **37**(14): 2320–2322.
- [8] Kumar A, Sharma S, Tripathi VD, et al. Synthesis of chalcones and flavanones using Julia-Kocienski olefination [J]. *Tetrahedron*, 2010, **66**(48): 9445–9449.
- [9] Bestmann HJ, Arnason B. Reaktionen mit phosphin-alkylenen, II. C-acylierung von phosphin-alkylenen. ein neuer weg zur synthese von ketonen [J]. *Chem Ber*, 1962, **95**(6): 1513–1527.
- [10] Tripathi S, Kapoor R, Yadav LDS. Visible light activated radical denitrative benzylation of  $\beta$ -nitrostyrenes: a photocatalytic approach to chalcones [J]. *Adv Synth Catal*, 2018, **360**(7): 1407–1413.
- [11] Parveen I, Khan D, Ahmed N. Regioselective hydrodehalogenation of aromatic  $\alpha$ - and  $\beta$ -halo carbonyl compounds by CuI in isopropanol [J]. *Eur J Org Chem*, 2019, **2019**(4): 759–764.
- [12] Mellado M, Madrid A, Reyna M, et al. Synthesis of chalcones with antiproliferative activity on the SH-SY<sub>5</sub>Y neuroblastoma cell line: quantitative structure-activity relationship models [J]. *Med Chem Res*, 2018, **27**(11/12): 2414–2425.
- [13] Wu YF, Zhou GL, Meng QW, et al. Visible light-induced aerobic epoxidation of  $\alpha$ , $\beta$ -unsaturated ketones mediated by amidines [J]. *J Org Chem*, 2018, **83**(21): 13051–13062.
- [14] Thomson CJ, Barber DM, Dioxon DJ. One-pot catalytic enantioselective synthesis of 2-pyrazolines [J]. *J Angew Chem Int Edit*, 2019, **58**(8): 2469–2473.
- [15] Wang C, Huang LY, Wang FZ, et al. Highly efficient synthesis of aryl ketones by PEPPSI-palladium catalyzed acylative Suzuki coupling of amides with diarylborinic acids [J]. *Tetrahedron Lett*, 2018, **59**(23): 2299–2301.
- [16] Zhang ML, Xi J, Ruzi R, et al. Domino-fluorination-protodefluorination enables decarboxylative cross-coupling of  $\alpha$ -oxocarboxylic acids with styrene via photoredox catalysis [J]. *J Org Chem*, 2017, **82**(18): 9305–9311.
- [17] Abdel-Halim M, Keeton AB, Gurpinar E, et al. Trisubstituted and tetrasubstituted pyrazolines as a novel class of cell-growth inhibitors in tumor cells with wild type p53 [J]. *Bioorg Med Chem*, 2013, **21**(23): 7343–7356.
- [18] Ahmed MG, Romman U, Ahmed SM, et al. Synthesis and correlation of spectral properties of some substituted 1,3-diphenyl-2-propen-1-ones [J]. *Bangladesh J Sci Ind Res*, 1970, **42**(1): 45–52.